Navigation Links
Encision Reports Fourth Quarter and Fiscal Year 2013 Results
Date:5/14/2013

BOULDER, Colo., May 14, 2013 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 fourth quarter and fiscal year ended March 31, 2013.

The Company posted quarterly product revenue of $2.650 million and quarterly service revenue of $87 thousand for a quarterly net loss of $279 thousand, or $(0.03) per share. These results compare to product revenue of $2.873 million and service revenue of $497 thousand for net income of $40 thousand, or $0.01 per share, in the year-ago quarter. Gross margin on product revenue was 59.4 percent in both quarters. Interest and other expense, net includes $64 thousand for the medical device excise tax that started January 1, 2013.

The Company posted fiscal year product revenue of $11.216 million and fiscal year service revenue of $551 thousand for a fiscal year net loss of $616 thousand, or $(0.08) per share. These results compare to product revenue of $11.226 million and service revenue of $1.763 million for a net loss of $531 thousand, or $(0.08) per share, in the year-ago fiscal year. Product gross margin was 57.5 percent compared to 54 percent in the year-ago fiscal year. In the year-ago fiscal year, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of certain electrode product.

"Overall, we were disappointed that our product revenue for the fourth quarter decreased on a year over year basis," said Fred Perner , President and CEO. "While we continue to be excited about several recent product introductions, the deliberate nature of our launch efforts prevented those products from making an impact on our fourth quarter product revenues. We are addressing the issues that caused our core product revenues to decline and are making the appropriate adjustments. As examples, John Halt , a former Area VP for Smith & Nephew, joined the company at the end of the fourth quarter as Eastern Regional Manager and Rob Tierney , former VP of Sales for Viking Medical, was added as an independent representative in the Northeast with the intent of building a larger distribution network in that region. Finally, our service revenue lagged last year's pace due to a project that was phased out by a strategic partner at the beginning of this fiscal year."

"The Company launched several new products during the fourth quarter. These new products include our new EM3 AEM® Monitor, a disposable fixed tip electrode product, and a disposable suction-irrigation electrode product, both of which possess hand control capabilities to complement the EM3 AEM Monitor. The EM3 AEM monitor includes an integrated hand control function, which allows the physician to easily use both our hand and foot activated AEM instruments; an intuitive user interface to ensure quick and easy setup; improved alarm troubleshooting through its active control; and, fail-safe AEM technology."

"In addition to our new product introductions, we announced an agreement in April with Virtual Ports Ltd. for exclusive distribution rights to their laparoscopic organ retraction products in the United States and believe these unique products complement our core electrosurgery platform very well."

"In April and May of calendar year 2013, to align our expenses with our current revenue, we made material expense reductions across all departments within our Company. On an annualized basis, the expense reduction exceeded $1.5 million and included a significant reduction of our workforce."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2012 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

 Encision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited)March 31, 2013March 31, 2012ASSETSCash and cash equivalents$
26$
565Accounts receivable, net9861,428Inventories, net2,9292,489Prepaid expenses6628Total current assets4,1074,510Equipment, net1,6291,619Patents, net238273Other assets97Total assets$ 5,983$ 6,409LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$   824$ 1,040Accrued compensation319283Other accrued liabilities446349Total current liabilities1,5891,672Common stock and additional paid-in capital21,57021,297Accumulated (deficit)(17,176)(16,560)Total shareholders' equity4,3944,737Total liabilities and shareholders' equity$ 5,983$  6,409 Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedFiscal Years EndedMarch 31, 2013March 31, 2012March 31, 2013March 31, 2012Net revenue:Product$ 2,650$ 2,873$11,216$11,226Service874975511,763Total revenue2,7373,37011,76712,989Cost of revenue:Product1,0761,1674,7695,148Service152265463816Total cost of revenue1,2281,4325,2325,964Gross profit1,5091,9386,5357,025Operating expenses:Sales and marketing9021,0203,6174,329General and administrative3595311,7121,819Research and development4633381,7561,349Total operating expenses1,7241,8897,0857,497Operating income (loss)(215)49(550)(472)Interest and other expense, net(64)(9)(66)(59)Loss before provision for income taxes(279)40(616)(531)Provision for income taxes––––––––Net income (loss)$  (279)$
40$
(616)$  (531)Net income (loss) per share—basic and diluted$ (0.03)$  0.01$   (0.08)$ (0.08)Basic weighted average number of shares8,2106,4888,2006,463Diluted weighted average number of shares8,2106,4908,2006,463


'/>"/>
SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports First Quarter of Fiscal Year 2013 Results
2. Encision Reports Second Quarter of Fiscal Year 2013 Results
3. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
4. Encision Inc. and Virtual Ports Ltd. Announce Exclusive Distribution Agreement for Laparoscopic Surgery Devices
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):